01.07 14:17 | dpa-AFX: AbbVie's Robert Michael Assumes Role Of CEO |
01.07 14:02 | dpa-AFX: *ABBVIE SAYS ROBERT MICHAEL ASSUMED ROLE OF CEO |
28.06 08:14 | dpa-AFX: AbbVie: CHMP Adopts Positive Opinion Recommending Conditional Marketing Authorization Of Epcoritamab |
28.06 08:04 | dpa-AFX: *ABBVIE GETS POSITIVE CHMP OPINION FOR EPCORITAMAB FOR TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA |
27.06 17:00 | dpa-AFX: AbbVie Acquires Celsius Therapeutics For $250 Mln |
27.06 15:31 | dpa-AFX: *ABBVIE ACQUIRES CELSIUS THERAPEUTICS FOR $250 MLN IN CASH |
27.06 14:32 | dpa-AFX: *ALLERGAN AESTHETICS LAUNCHES ALLE PAYMENT PLANS POWERED BY CHERRY |
27.06 02:52 | dpa-AFX: Genmab's EPKINLY Receives FDA Accelerated Approval For R/R Follicular Lymphoma |
25.06 14:28 | dpa-AFX: AbbVie: FDA Issues CRL For ABBV-951 |
25.06 14:17 | dpa-AFX: *ABBVIE RECEIVES FDA COMPLETE RESPONSE LETTER FOR ABBV-951 IN PARKINSON'S DISEASE TREATMENT |
21.06 14:03 | dpa-AFX: *ABBVIE (ABBV) DECLARES QUARTERLY DIVIDEND OF $ 1.55, RECORD DATE 7/15/2024 |
21.06 14:02 | dpa-AFX: *ABBVIE DECLARES QUARTERLY CASH DIVIDEND OF $1.55/SHR; PAYABLE AUGUST 15/RECORD JULY 15 |
20.06 14:02 | dpa-AFX: *ABBVIE APPOINTS ROXANNE S. AUSTIN AS LEAD INDEPENDENT DIRECTOR, EFFECTIVE JULY 1 |
19.06 07:26 | dpa-AFX: AbbVie's Skyrizi Gets Approval In US For Ulcerative Colitis |
13.06 14:31 | dpa-AFX: AbbVie To Receive License From FutureGen To Develop, Commercialize FG-M701 |
13.06 14:02 | dpa-AFX: *ABBVIE AND FUTUREGEN STRIKE $1.71 BLN DEAL TO DEVELOP NEXT-GENERATION THERAPY FOR INFLAMMATORY BOWEL DISEASE |
13.06 14:00 | dpa-AFX: *ABBVIE, FUTUREGEN TO DEVELOP NEXT-GENERATION THERAPY FOR INFLAMMATORY BOWEL DISEASE |
12.06 15:02 | dpa-AFX: AbbVie To Present At Goldman Sachs Global Healthcare Conference; Webcast At 10:00 AM ET |
06.06 15:34 | dpa-AFX: AbbVie Reports Positive Results From Phase 2 PICCOLO Trial Of Mirvetuximab Soravtansine In PSOC |
06.06 14:47 | dpa-AFX: *ABBVIE ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN OVARIAN CANCER |
|